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Abstract
Chemotherapeutic agents produce from numerous sources such as animals, 
plants and micro-organisms are derived from the natural products. Although the 
existing therapeutic pipeline lacks fungal-derived metabolites, but hundreds of 
secondary metabolites derived from fungi are known to be possible chemothera-
pies. Over the past three decades, several secondary metabolites such as flavonoids, 
alkaloids, phenolic and polyketides have been developed by Saccharomyces cerevi-
siae species with exciting activities that considered valued for the growth of new 
chemotherapeutic agents. Many secondary metabolites are protective compounds 
which prevent abiotic and biotic stresses, i.e. predation, infection, drought and 
ultraviolet. Though not taking part in a living cell’s central metabolism, secondary 
metabolites play an important role in the function of an organism. Nevertheless, 
due to slow biomass build-up and inadequate synthesis by the natural host the yield 
of secondary metabolites is low by direct isolation. A detailed comprehension of 
biosynthetic pathways for development of secondary metabolites are necessary for 
S. cerevisiae biotransformation. These metabolites have higher inhibitory effect, 
specificity among cancer and normal cells, and the mechanism of non-apoptotic 
cell killing. This study shows the significance of bioactive compounds produced by  
S. cerevisiae species with their possible activity and value in chemotherapeutic drugs 
pipeline. The isolation and alteration of these natural secondary metabolites would 
promote the development of chemotherapeutic drugs.
Keywords: Saccharomyces cerevisiae, secondary metabolites, anticancer activity, 
synthetic biology, bioactive compounds
1. Introduction
Yeast is a single-celled eukaryotic microorganism that belongs to the kingdom of 
fungi. About 1500 yeast species have been correctly described since the discovery 
of the first yeast [1]. Yet 1% of all known fungal members are stated to be yeast 
species. Saccharomyces cerevisiae, budding yeas, also represents a typical industrial 
microorganism used in basic molecular biology research as a main model organism 
and was the first eukaryotic organism to have completely sequenced its genome. 
Saccharomyces
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A single-cell fungus, Saccharomyces cerevisiae, is also known as a Baker’s yeast [2]. 
Saccharomyces cerevisiae is the eukaryotic microorganism most extensively studied, 
which allows us to understand the eukaryotic cell biology and subsequently the 
physiology of human. For several hundred years, in food processing and alcoholic 
drinks, S. cerevisiae have been used, and this organism is still used today in a variety 
of different pharmaceutical processes. It functions very well as it is non-pathogenic 
and is classified by GRAS organism (generally regarded as safe) due to the long his-
tory of use in the development of consumables such as ethanol and baker’s yeast [3].
The sum of all organismic biochemical reactions can be described as metabo-
lism. Metabolites are the products and intermediates of metabolism and are gener-
ally limited to small molecules. Natural products come from a variety of sources, 
including animal species, land-based plants, aquatic organisms, land invertebrates 
and vertebrates, microorganisms as secondary metabolite products [4]. The word 
“secondary” proposed by A. Kossel in 1891 means that while in any living cell 
primary metabolites are present, the secondary metabolites are only present at a by-
product and are of no significant importance to the life of the organism. Although 
the primary metabolism derives secondary metabolites, these secondary metabo-
lites do not constitute the organism’s fundamental molecular framework. Although 
the secondary metabolites do not participate in central metabolic processes of 
a living cell, they play an important role in the function of an organism. Many 
secondary bioactive compounds defend against biotic and abiotic and biotic stresses 
including predation, cancer, drought and ultraviolet radiations. Its absence does not 
reduce the life of an organism, which is a feature contrary to primary metabolite, 
instantly, but largely affected the organism’ survival. Currently there are a range of 
analytical platforms for metabolomics research, among which are including mass 
spectrometry direct infusion (MS), gas chromatography liked to mass spectrometry 
(GC– MS), gas chromatography linking to mass spectrometry two-dimensional 
(GC, GC– MS), liquid chromatography coupled to mass spectrometry (LC–MS), 
capillary electrophoresis to mass spectrometry coupling (CE–MS), and proton 
nuclear magnetic resonance spectroscopy (1H NMR) [5].
These complex structural and chemical molecules serve as an excellent thera-
peutic class to cure many diseases. Around 80 percent of all drugs were derived 
from plant sources at the beginning of 1900. Alexander Fleming’s discovery of 
penicillin from Penicillium notatum in 1928 marked a major change as a source of 
natural product from plants to micro-organisms. In medicine, agriculture, food 
industry and scientific research microorganism-derived compounds since then 
have been used [6]. But, due to the slow accumulation by biomass and inadequate 
synthesis by the host, the production of secondary metabolites by direct isola-
tion is poor. Exhaustive awareness of biosynthetic pathways for the production of 
secondary metabolites are necessary for the development of S. cerevisiae biotrans-
formation. Progress in synthetic biology has made it possible to develop a number 
of bioinformatics tools that can be utilized to create new regulatory elements and 
secondary metabolite synthesis pathways [7].
Because of its similar metabolism Saccharomyces cerevisiae was used as a biologi-
cally similar model for higher eukaryote organisms. The expression of heteroge-
neous pathways is less difficult relative to other kinds because of its eukaryotic 
nature. For example, prokaryotes do not conduct any post-translational modifica-
tions, and protein miss-folding and membrane translation can be an annoyance [8]. 
During preclinical or clinical testing, a well-characterized yeast metabolite, such 
as flavonoids, alkaloids, phenolic and polyketides, exhibit remarkable anti-tumor 
properties unexpectedly. Although its basic action mechanism is still being studied, 
evidence shows that its actions are operationally directed toward core regulatory 
pathways and dysregulated enzymes during cancer pathogenesis.
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Since ancient time, from the days of the Pharaohs in ancient Egypt, cancer 
continues to plague humanity. It derives its name from Hippocrates, father of 
medicine, who had been using the Greek-named “Karkinos” to talk about tumors, 
nevertheless these earliest view about this infection are different from modern 
concept. Cancer has been characterized as an irregular growth in cells caused by 
several changes in gene-expression leading to dysregulated equilibrium between 
death of cell and proliferation eventually developing into cell populations that 
can invade and metastasize tissues in distant sites and cause severe host death if 
left unsanctioned according to the World Health Organization (WHO). About 60 
percent of all anticancer medications currently available in clinics are natural or 
derived from natural product modification substances. In the 1950s interest in the 
discovery and production of vinblastine, vinka alkaloids and vincristine, and later 
taxol from Pacific yew bark, Taxus brevifolia, in the pursuit of natural anticancer 
agents began earnestly. Then, our awareness of the metabolites of S. cerevisiae 
have also been further progressed in cancer therapy and have reported antitumor 
action against the overwhelming majority of cancers, like lymphoma, leukemia and 
solid tumors. Far from the suppression of tumor development, the delay of tumor 
progression, and an effect on tumor-cell metastatic and invading therapy, these 
metabolite combinations have almost all demonstrated strong therapeutic benefit at 
the preclinical level. Some of these allegedly promising metabolite compounds are 
discussed individually below [9].
2. Production of secondary metabolites via S. cerevisiae
Apart from essential metabolites (carbons, proteins, amino acids, vitamins, 
acetones, ethanol, etc.), S. cerevisiae offers a wide range of secondary metabolites 
during active cell development, including toxins, antibiotics, fatty acids, alkaloids, 
alcohols, ketones etc. Secondary metabolites (SM’s), which are not necessary for 
organism growth, are classified as diverse low molecular-weighted compounds. For 
a number of purposes, S. cerevisiae use secondary metabolites such as stress preven-
tion, predation defense, competitiveness, communications, pathogenicity and 
exposure of other organisms. A small number of primary metabolism precursor 
metabolites are used to biosynthesize secondary metabolites [10].
A number of bioactive compounds, including terpenoids, polyketides, alkaloids 
and non-ribosomal peptides can be produced in Saccharomyces cerevisiae (Figure 1). 
Such precursors are mainly short chain carboxylic acids (for example, acetyl-coA) or 
amino acids in Saccharomyces cerevisiae species which are connected to synthesized 
polyketides by backbone enzymes such as polyketide synthases (PKSs). Terpenoids 
production is catalyzed by terpene cyclase and production starting from dimethyl 
allyl diphosphate derived from (or isoprene). Non-ribosomal peptide synthetases 
(NRPSs) using modified and natural amino acids to synthesize non-ribosomal 
peptides. Diverse enzymes are used to catalyze the synthesis of alkaloids from amino 
acid. These secondary metabolites can naturally be synthesized as industrial products, 
particularly pharmaceutical products, from host (native) cells.
Many other reports have shown that the genes involved in biosynthetic second-
ary metabolites are known as biosynthetic gene clusters (BGCs). This have been 
shown that genes that encode significant biosynthesis (for example; polyketides 
synthase) are supplementary enzymes and precursors in the pathways of bio-
synthesis. Consequently, all significant genes are discovered in the BGCs that 
participate in the synthesis of bioactive compounds [11, 12]. The production and 
complementary regulation of catalytic properties can produce incredibly useful 
secondary metabolites for these biochemical transformations BGC enzymes [13].  
Saccharomyces
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The methods and technology used to improve pharmaceutical production of 
secondary metabolites in the S. cerevisiae have advanced rapidly in recent years.
We discuss below the progress in developing biosynthetic pathways of 
Saccharomyces cerevisiae’ secondary metabolites with anticancer potential: alkaloids, 
phenolic, terpenoids, polyketides, non-ribosomal peptides, and vitamin C.
3. Alkaloids
Several studies have used S. cerevisiae in recent years as a host to engineer the 
biosynthetic process of alkaloids. Alkaloids are complex nitrogen molecules that are 
extremely bioactive. There are reportedly approximately 50 alkaloid medications, 
including vincristine (cancer drug), codeine (analgesic drug) and noscapine (anti-
tussive drug). They are unique for the cell cycle and the process, because they block 
metaphase (M phase) in mitosis. They block tubulin’s ability to form microtubules 
via polymerization. Dysfunctional spindle structures, avoid chromosome separa-
tion and cell proliferation. Strictosidine, which had been synthesized by novo, was 
the earliest study of alkaloid plant origin in Saccharomyces cerevisiae strains [14]. 
Strictosidine is a significant intermediate product in the terpenoids Indole alkaloids 
(TIAs) biosynthesis that include vincristine (antitumor) and ajmalicine (anti-
hypertensive) [15].
The metabolic course of Saccharomyces cerevisiae for protoberberine alkaloid 
(S) canadine from racnorlaudanosolin has been optimized by Galanie et al. [16]. 
The secondary metabolite of Berberine has numerous pharmacological effects, 
such as antidiabetics, antibacterial, anti-ulcerones and anti-inflammatory effects. 
In vivo and vitro experiments with berberine, the results of arresting cell cycle 
during G1 or G2/M and apoptosis of tumor cell were shown to be anti-cancer activ-
ity. Berberine also was found to induce autophagy and stress in the endoplasmic 
reticulum, resulting in the invasion and inhibition of the tumor cells. Berberine has 
been proven to lower angiogenesis by decreasing expression of VEGF in addition to 
its apoptotic effects. The cancer cell migration was also decreased. In the respective 
Figure 1. 
A short description of the formation pathways of secondary metabolites [11, 12]. Four sub-groups of 
microorganism and plant-generative metabolites involve terpenoids, polyketides, non-ribosomal peptides and 
alkaloids. Biosynthetic genes (BGC’s) are structurally classified into the genes that encrypt major biosynthetic 
enzymes, supplementary enzymes, precursors in the process of biosynthesizing, resistance factors or transporters 
in secondary metabolite formation.
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complexes, Berberine attaches to DNA or RNA. Berberine also stimulates P53, 
which contributes to cell cycle arrest and apoptosis. Berberine has been shown to 
induce apoptosis as well via DNA interactions and pathways that are dependent on 
mitochondrial [17].
4. Phenolic
Phenolic are a large category of secondary plant metabolites that have at least 
one hydroxylated ring. Flavonoids and stilbenes are two groups of metabolites 
highly appreciated as a nutrient and therapeutic agent among the phenolic devel-
oped by phenylpropanoid pathways in the plant [18]. As a host cell, Saccharomyces 
cerevisiae is well equipped to promote phenolic compound biosynthesis. The fol-
lowing phases include cancer development: initiation, development, proliferation, 
invasion and metastasis. Initiation links by free radicals, inflammatory mediators, 
radiation, smoke of cigarette that damage the DNA-product, which can cause 
genetic mutation and replication of cells which are mutated results to cause carcino-
genesis [19].
It has been noted that phenolic compounds i.e. ellagic acid and delphinidin show 
significant protective effects for example, apoptotic activity in colon cancer cells. 
In prostate, liver and leukemia cancer cells, delphinidin also showed significant 
activity. Cell apoptosis can also be caused by phenolic compounds. The mechanisms 
of invasion and migration of human cancer are also updated (Figure 2) [20].
5. Flavonoids
The Saccharomyces cerevisiae strains have been developed by researchers, 
which synthesize various flavonoids, from the main phenolic intermediates to 
flavones, flavanones, flavonols and isoflavones. Phenylalanine is transformed into 
p-coumaric acid, a common phenylpropanoid precursor, in two sequence reac-
tions in the initial steps of the phenylpropanoid pathway. S. cerevisiae is an ideal 
flavonoid host strain. One of the first studies on S. cerevisiae for flavonoid produc-
tion was carried out according to [21]. The first flavonoid analysis was published 
on the synthesis of naringenin, major intermediate of flavonoid, from glucose in 
engineered Saccharomyces cerevisiae [22]. In Saccharomyces cerevisiae p-coumaric 
acid was used as a precursor for other flavonoids including apigenin, chrysin 
and luteolin. Anti-inflammatory, cardio-protective and anticancer effects were 
observed for quercetin, kaempferol, and fisetin [23].
Figure 2. 
Potential of secondary metabolite protective mechanisms for cancer management [17].
Saccharomyces
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More flavonoid intake has been reported to reduce cancer risk. In this respect, 
there have been reports of a variety of mechanisms including arresting of cell 
cycle, proliferation inhibition, apoptosis induction, anti-oxidation etc. These 
flavonoid extracts’ cytotoxic activity makes them capable to produce cancer drugs. 
Flavonoids from Saccharomyces cerevisiae have potential to treat cancer treatment 
at all stages is therefore important for the recognition of harmless constituents 
against cancer as important for chemotherapy. Therefore, for producing cancer 
medicines, it is important to distinguish effective components from the yeast 
strain. Flavonoid-treated HeLa cells displayed apoptosis and loss of mitochondrial 
membrane potential (MMP). The toxic effect of flavonoid extracts makes them 
attractive candidates for cancer drug development. Such treatments have been 
found to inhibit growth across many lines of cancer cell, including cancer of the 
colon, breast cancer, carcinoma of squamous cell and hepatocellular carcinoma etc. 
Another study concerning bioactive flavonol “fisetin” found that fistein treatment 
caused cell viability by regulating the arresting G1 phase of human in melanoma 
cells [24].
6. Terpenoids
Many terpenoids were developed by engineering the related metabolic pathways 
in Saccharomyces cerevisiae. The first study about the medically useful development 
of terpenoids in yeast was the amorphadiene synthesis in Saccharomyces cerevisiae. 
The sigma ling of NF- κB, the key regulator in pathogenesis for cancer and inflam-
mation, can be inhibited by natural terpenoids. Various mechanisms, such as the 
induction of apoptosis, have been found in terpenoid cancer. The natural terpenoids 
are quite well identified as NF-κB signaling inhibitors. Yeast also produces taxol 
(class of di-terpenoid), which is a common cancer medicine [25]. Saccharomyces 
cerevisiae has been metabolically adapted for the synthesis of taxa diene as a pri-
mary trial for taxol synthesis in a microbial host [26]. Paclitaxel (generally called 
taxol) is a common and strong drug used in chemotherapy for cancer. Taxol has 
the anti-tumor property due to its attachment to microtubule protein i.e. β-tubulin. 
As a result, the micro tubular dynamics have been suppressed and acetylation of 
α-tubulin protein has been increased. Mitosis can be prevented by increase in micro 
tubular and thus contributes to the cell’s death.
The carotenoids were the first kind of isoprenoids formed in the Saccharomyces 
cerevisiae. These compounds are found to cardiovascular and osteoporosis anti-
oxidant with therapeutic effects and to have anticancer activity by the activation of 
the NF-κB signaling pathway. LPS are reduced by signaling caused by β-carotene. 
It also reduces the IκB protein and prevents p65 subunit nuclear translocation and 
also prevent the NF-κB complex binding with DNA. β-carotene prevents cancer 
progression by virtue of its proxidant function [27].
7. Polyketides
Polyketides form a large group of bioactive compounds, which vary in pharma-
cology and structure, and cover different drugs like antibiotics and antitumor. The 
polyketides are synthesized by large enzymes called polyketide (PKS) as secondary 
metabolites in particular by fungi and bacteria. The Synthesis of dihydrochalcones 
(DHCs) is an example of the polyketide development of metabolic Saccharomyces 
cerevisiae strain. One polyketide derivative with antidiabetic and antioxidant 
activity is DHCs such as nothofagin and phlorizin. Preclinical trials indicate that its 
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primary effect is to disrupt the dynamics of microtubule by reducing micro tubular 
polymerization and contribute to apoptosis. However, the mechanisms used to 
regulate eribulin’s action were not fully elucidated [28]. Other pre-clinical studies in 
eribulin have demonstrated its ability in breast and colon cancer to suppress tumor 
growth in xenograft models of mouse. In metastatic breast cancer trials, clinical 
studies have shown that this compound is viable. Additional phase III analysis 
showed that eribulin as though only other two therapeutic drugs (taxane and 
anthracyclines) increases overall survival in pre-treated patients with severe breast 
cancer (Figure 3) [29].
Activation of the caspase is conducted along two separate routes: the cell mem-
brane mediated pathway of the death recipient and the mitochondrial pathways. 
Rising Bax protein levels with a related decrease in the Bcl-2 protein have been 
shown by the two studies. A rise in the Bax/Bcl-2 ratio is well known to encour-
age cytochrome c release from mitochondria into the cytosol, culminating in the 
triggering of caspase-3, which is a cause for apoptosis initiation. A variety of signal 
transduction pathways and regulatory pathways contribute, among other things, 
to the upregulation of apoptosis genes are recorded to involve protein–protein 
interactions (PPIs) and their associated protein [30]. STAT-3 seem to have an effect 
on the migration of the tumor and glioblastoma cells, non-small cell lung cancer 
(NSCLC), renal system of human which have shown a metabolite disturb this 
Figure 3. 
Targets of Saccharomyces cerevisiae secondary metabolites in tumor cells [9].
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system which indicates that the mechanism is likely to slow or suppress solid tumors 
in the metastatic process [31].
8. Non-ribosomal peptides (NRPSs)
Gurma is a 35-residue peptide widely used as a medical product in sweet-tasting 
transduction studies because of its ability to specifically inhibit neural responses 
for sweet matter in rats and mice is an example of the non-ribosomal peptide 
synthesis in modified yeast. Early research has shown that NRPSs are involved 
in the development of some of our key antiviral, anticancer, antibacterial and 
immunosuppressant medicines even though they are not progenitors of this ribo-
some. It has been determined the bleomycins are a group of glycosylated peptides 
which Umezawa and his colleagues found to be active against cancer in the 1960s. 
Bleomycin A2 and B2 is a major component of the clinical medicine, blenoxane. 
Carcinoma of cell squamous, lymphomas, esophageal cancer, testicular cancer and 
recalcitrant warts have been treated with blenoxane. This iron-bleomycin complex, 
mostly ferrous ions which interacts with oxygen and creates reactive free radi-
cal. Specifically, the free radicals respond to the abstraction of DNA deoxyribose 
hydrogen from C4’ and lead to one or two-strand breaks, mainly of G-T and G-C at 
pyrimidines [32].
Several compounds for the production of novel anticancer drugs have recently 
come into being. However, the pathways involved in the cytotoxicity of these 
compounds in tumor cell lines are still widely ignored but many studies point to 
a significance in apoptosis. For example, a number of compounds impeding cell 
growth in a wide range of cell lines of cancer have been shown to be still poorly 
elucidated by which canner cells are hampered. Compounds were identified in some 
cases to cause cell death by the triggering of the apoptotic pathway; however, more 
studies were required in the mechanisms involved apoptosis. Some compounds cre-
ated an imbalance in the ability of the cell redox, with mitochondria playing a key 
role in this phase. Further studies are required to explain this, however. A further 
impaired process is cell cycle, primarily as a result of actin and micro tubular fila-
ment interruption, yet only a few studies are conducted to link marine NRPs with 
cell cycle alterations, and further research are necessary to clarify their intervention 
in the process [33].
9. Vitamin C
L-ascorbic acid (Vitamin C and L-AA or) is a water-soluble effective antioxidant 
used as a ROS scavenger to defend against or at least reduce the harmful effects 
caused by ROS in most eukaryotic species. ROS is a common source of various types 
of cancer and considered vitamin C have a beneficial impact on reductions of lung, 
colorectal and stomach cancer [34]. On the other hand, vitamin C can, under some 
circumstances, enhance the production of ROS and may have adverse effects under 
some circumstances [35].
However, the ability of yeast cells to generate L-AA is normal. Erythro-ascorbic 
acid is instead present at a low concentration in yeast cells as a structurally con-
nected substance with chemical composition identical to L-AA. The vitamin C 
biosynthesis from D-glucose in S. cerevisiae cells that was recombinant by using 
a plant paths is first recorded according to [36]. In two distinct strains, ascorbic 
acid accumulation was shown to be effective, and the effect from a distinct genetic 
context was studied in parallel [37].
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10. Future perspectives
Further studies on the kinds of chemical components and the purification of 
different bioactive groupings could show the full capacity for certain pathogenic 
microbes inhibited by the Saccharomyces cerevisiae extract. The creation of a catalog 
of Saccharomyces cerevisiae processing hosts which are produced for the supply by 
the overproduction of central metabolites of sufficient precursors for heterologous 
pathways introduced can be aimed at future efforts in the sector. These modified 
strains often have the effect of modifying the functioning of organelle and cell 
membrane processes in order to enable the efficient use of substrates, product 
exports, intermediate retention and partitioning.
Additional crucial components are the compatibility between the introduced 
foreign secondary metabolite genes and the Saccharomyces cerevisiae host, includ-
ing highly enhanced host pathway expression, metabolic stress/contamination, 
sufficient resistance/export of secondary metabolites etc. The strengthening of 
the hierarchical regulatory waterfalls within the host cell and the incorporation 
of appropriate promoters into the inserted BGC could help to improve the BGC 
expression for the secondary bioactive metabolite of an engineered host. Then, 
the resistant and exporting genes derived from or from original biosynthetic gene 
clusters or selected from other clusters of genes, other secondary source metabo-
lites or even environment metagenomes might reduce the toxicity and metabolic 
burden on the host cell due to synthesis of secondary metabolites. In the coming 
years activities in other yeast species will be further investigated in order to identify 
additional results and obtain more high-performance products in this area instead 
of Saccharomyces cerevisiae in pharmaceutical secondary metabolites.
11. Conclusion
In summing up this paper, remarkable developments in the field of yeast cell 
and molecular biology have taken place in the last two decades, especially as cell 
engineering, genome sequencing and synthetic technology have grown rapidly. 
Many useful pharmaceuticals and metabolites were developed using modified 
Saccharomyces cerevisiae. These results support a strong prediction that secondary 
metabolites from Saccharomyces cerevisiae can be perceived to occur as single pharma-
cological compounds. The metabolites also target key regulatory pathways in cancer 
cells, normal cells and tissues. Until human trials are launched on cancer subjects, 
fungal metabolites must, however, undergo stringent quality control and pharma-
cological dose-scaling evaluations. In addition, high-end screening methods need 
to be standardized because new metabolites are constantly identified for the yeast 
metabolite library survey. Isolating and altering these secondary metabolites would 
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